Tempus AI has delivered a strong year to date gain, and a stream of new partnerships and regulatory milestones has helped keep the stock in focus. With the share price moving faster than many investors can track the underlying business, the key issue now is whether Tempus AI's current market value is still grounded in its sales.
-
Year to date, the stock is up 25.8%, which puts real pressure on the question of whether recent top line performance can support that kind of re-rating based on revenue alone.
-
Recent large pharma collaborations and product clearances can shape expectations for future sales, since they may influence how quickly Tempus AI converts its data assets and clinical tools into contracted revenue.
-
Your read on Tempus AI is one view; the desks covering it have another. See what analysts think Tempus AI's shares could be worth .
For investors, the debate is whether Tempus AI's current share price is appropriately anchored to the level and trajectory of its sales.
If you want to stress test this same sales driven valuation question beyond Tempus AI, it can help to compare it with other 33 healthcare AI stocks .
Does Tempus AI Look Pricey on Sales?
P/S suits Tempus AI because the business is still loss making and investors are effectively paying for its revenue base and commercial footprint rather than current earnings. At about 9.9x P/S, the stock trades above both the Life Sciences industry average of roughly 4.7x and the nearer peer group at about 7.8x.
The fair P/S multiple implied by the model, which blends Tempus AI's growth profile, margins, scale and risk into a single yardstick, sits below the current 9.9x, so the shares screen as overvalued on this framework. Despite the recent Q3 revenue beat, raised full year guidance and fresh pharma deals, that premium suggests investors are already paying up for a strong execution story and a rich pipeline of contracts. Explore the numbers behind Tempus AI's P/S valuation .
The Tempus AI Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Tempus AI pick up where the P/S debate leaves off by spelling out which paths for Tempus AI's future revenue, profitability and earnings would need to play out for the shares to look meaningfully higher or lower than today. Rather than relying on a single valuation number, each scenario lays out the specific assumptions behind its view of fair value so you can track those against actual results over time.
Tempus AI attracts two very different readings from the community, with one group seeing more upside than the other at today's price.
Bull case: 22% undervalued
"The project to assemble 100,000 whole genomes with longitudinal clinical data, with a long term objective of one million genomes, sets up a proprietary multimodal dataset..."
Discover why this Narrative puts Tempus AI at 22% undervalued .
Bear case: roughly fairly valued
"Tempus carries significant debt, is not yet consistently profitable, and expectations for AI remain high..."
Explore why this Narrative puts Tempus AI at roughly fairly valued .
One more Tempus AI angle that could change how you see this stock
Everything so far has focused on what Tempus AI looks like today, yet professional analysts have already mapped out where they think this business could be in a few years, and that forward view can be a useful cross check. Explore where analysts expect Tempus AI to be in a few years .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TEM .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
